Chokethawee Ouejiaraphant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chokethawee Ouejiaraphant has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Arunchai Chang
Division of Gastroenterology, Department of Internal Medicine, Hatyai Hospital, Songkhla, Thailand
1 shared publication - Attapon Rattanasupar
Division of Gastroenterology, Department of Internal Medicine, Hatyai Hospital, Songkhla, Thailand
1 shared publication - Atthaphong Phongphithakchai
Nephrology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
1 shared publication - Keerati Akarapatima
Division of Gastroenterology, Department of Internal Medicine, Hatyai Hospital, Songkhla, Thailand
1 shared publication - Ussanee Boonsrirat
Prince of Songkla University, Hat Yai, Thailand
1 shared publication - Varayu Prachayakul
Siriraj Gastrointestinal Endoscopy Center, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
1 shared publication
Latest Publications
- Open Access
- 24 February 2022
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Identifying the optimal timing of renal replacement therapy initiation among critically ill patients on extracorporeal membrane oxygenation therapy
Introduction: Acute kidney injury (AKI) is one of the most frequent complications in patients with severe cardiopulmonary dysfunction on extracorporeal membrane oxygenation (ECMO) therapy. Although renal replacement therapy (RRT) is the standard of care for AKI, the timing of initiation of RRT remains controversial. Objectives: This study aimed to determine the optimal timing of RRT initiation among patients receiving ECMO therapy. Patients and Methods: We conducted a retrospective cohort study of 40 patients in a tertiary hospital centre from March 2014 until December 2019. The patients were divided into two groups according to the timing of RRT initiation, i.e. early RRT (within 72 hours) or late RRT after ECMO treatment. The primary outcome was 60-day mortality. The secondary outcomes were survival predictors of these patients. Results: The 60-day mortality was not significantly different between the two groups (76.9% in the early RRT initiation and 88.9% in the late group; P=0.321). The predictors of survival were RRT start within 72 hours of ECMO initiation (HR: 0.067, 95%, CI: 0.010-0.457), age ≥ 60 years (HR: 6.334, 95% CI: 1.268-31.625), fluid balance on day seven of ECMO (HR: 1.093, 95% CI: 1.007-1.187), and eGFR-EPI ≥ 60 mL/min/1.73 m2 (HR: 0.970, 95% CI: 0.946-0.996). Conclusion: Among patients with ECMO and RRT, early RRT within 72 hours of ECMO initiation was significantly associated with a decreased risk of death. Our findings suggest the survival benefit of early RRT in critically ill patients treated with ECMO.
- 24 February 2022
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
Open AccessIdentifying the optimal timing of renal replacement therapy initiation among critically ill patients on extracorporeal membrane oxygenation therapy
Introduction: Acute kidney injury (AKI) is one of the most frequent complications in patients with severe cardiopulmonary dysfunction on extracorporeal membrane oxygenation (ECMO) therapy. Although renal replacement therapy (RRT) is the standard of care for AKI, the timing of initiation of RRT remains controversial. Objectives: This study aimed to determine the optimal timing of RRT initiation among patients receiving ECMO therapy. Patients and Methods: We conducted a retrospective cohort study of 40 patients in a tertiary hospital centre from March 2014 until December 2019. The patients were divided into two groups according to the timing of RRT initiation, i.e. early RRT (within 72 hours) or late RRT after ECMO treatment. The primary outcome was 60-day mortality. The secondary outcomes were survival predictors of these patients. Results: The 60-day mortality was not significantly different between the two groups (76.9% in the early RRT initiation and 88.9% in the late group; P=0.321). The predictors of survival were RRT start within 72 hours of ECMO initiation (HR: 0.067, 95%, CI: 0.010-0.457), age ≥ 60 years (HR: 6.334, 95% CI: 1.268-31.625), fluid balance on day seven of ECMO (HR: 1.093, 95% CI: 1.007-1.187), and eGFR-EPI ≥ 60 mL/min/1.73 m2 (HR: 0.970, 95% CI: 0.946-0.996). Conclusion: Among patients with ECMO and RRT, early RRT within 72 hours of ECMO initiation was significantly associated with a decreased risk of death. Our findings suggest the survival benefit of early RRT in critically ill patients treated with ECMO.
- Open Access
- 30 March 2021
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 54 (2) , 211-221
Prospective Comparison of the AIMS65 Score, Glasgow-Blatchford Score, and Rockall Score for Predicting Clinical Outcomes in Patients with Variceal and Nonvariceal Upper Gastrointestinal Bleeding
This study aimed to determine the performance of the AIMS65 score (AIMS65), Glasgow-Blatchford score (GBS), and Rockall score (RS) in predicting outcomes in patients with upper gastrointestinal bleeding (UGIB), and to compare the results between patients with nonvariceal UGIB (NVUGIB) and those with variceal UGIB (VUGIB). We conducted a prospective observational study between March 2016 and December 2017. Receiver operating characteristic curve analysis was performed for all outcomes for comparison. The associations of all three scores with mortality were evaluated using multivariate logistic regression analysis. Of the total of 337 patients with UGIB, 267 patients (79.2%) had NVUGIB. AIMS65 was significantly associated (odds ratio [OR]=1.735; 95% confidence interval [CI]=1.148-2.620), RS was marginally associated (OR=1.225; 95% CI=0.973-1.543), but GBS was not associated (OR=1.017; 95% CI=0.890-1.163) with mortality risk in patients with UGIB. However, all three scores accurately predicted all other outcomes (all p0.05). Only AIMS65 precisely predicted mortality, the need for blood transfusion and the composite endpoint (all p<0.05) in patients with VUGIB. AIMS65 is superior to GBS and RS in predicting mortality in patients with UGIB, and also precisely predicts the need for blood transfusion and the composite endpoint in patients with VUGIB. No scoring system could satisfactorily predict rebleeding in all patients with UGIB.
- 30 March 2021
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 54 (2) , 211-221
Open AccessProspective Comparison of the AIMS65 Score, Glasgow-Blatchford Score, and Rockall Score for Predicting Clinical Outcomes in Patients with Variceal and Nonvariceal Upper Gastrointestinal Bleeding
This study aimed to determine the performance of the AIMS65 score (AIMS65), Glasgow-Blatchford score (GBS), and Rockall score (RS) in predicting outcomes in patients with upper gastrointestinal bleeding (UGIB), and to compare the results between patients with nonvariceal UGIB (NVUGIB) and those with variceal UGIB (VUGIB). We conducted a prospective observational study between March 2016 and December 2017. Receiver operating characteristic curve analysis was performed for all outcomes for comparison. The associations of all three scores with mortality were evaluated using multivariate logistic regression analysis. Of the total of 337 patients with UGIB, 267 patients (79.2%) had NVUGIB. AIMS65 was significantly associated (odds ratio [OR]=1.735; 95% confidence interval [CI]=1.148-2.620), RS was marginally associated (OR=1.225; 95% CI=0.973-1.543), but GBS was not associated (OR=1.017; 95% CI=0.890-1.163) with mortality risk in patients with UGIB. However, all three scores accurately predicted all other outcomes (all p0.05). Only AIMS65 precisely predicted mortality, the need for blood transfusion and the composite endpoint (all p<0.05) in patients with VUGIB. AIMS65 is superior to GBS and RS in predicting mortality in patients with UGIB, and also precisely predicts the need for blood transfusion and the composite endpoint in patients with VUGIB. No scoring system could satisfactorily predict rebleeding in all patients with UGIB.